June 24, 2003

News Release: GE Medical Systems and Cytogen Announce Marketing Alliance

GE Medical Systems, a unit of General Electric Company (NYSE: GE), announced at the 50th Annual Meeting of the Society of Nuclear Medicine that it has formed an alliance with Cytogen Corporation (Nasdaq: CYTO) to market a total molecular imaging system to help evaluate the extent and spread of prostate cancer by integrating GE Medical's Infinia(TM) Hawkeye(R) imaging system with Cytogen's ProstaScint(R) imaging agent. GE's revolutionary Infinia Hawkeye imaging system combines the anatomic detail of computed tomography (CT) with the molecular imaging data provided by nuclear medicine cameras using products such as Cytogen's ProstaScint. Infinia Hawkeye provides CT-based attenuation correction and localization for single-photon emission computed tomography (SPECT) studies that can help address the inherent limitations of SPECT imaging.

ProstaScint is a radiolabeled monoclonal antibody that specifically targets prostate-specific membrane antigen (PSMA). Due to the enhanced expression of PSMA by prostate cancer cells, the ProstaScint molecular imaging procedure can detect the cancer's extent and spread, particularly to lymph nodes, one of the common first sites of prostate cancer metastases in the body.

'The combining of CT data with ProstaScint SPECT data provides valuable additional guidance to the clinician in evaluating potential tumor sites,' said Professor Keith E. Britton, MD, Head of the Nuclear Medicine Department at St. Bartholomew's Hospital in London, UK. 'This technique will also be useful in enhancing other radioimmunoscintigraphic studies, such as the imaging of colon and ovarian cancer.'

'ProstaScint is a key contributor to the success of Infinia Hawkeye SPECT/CT molecular imaging of the prostate,'said Jeff Kao, General Manager, Nuclear Medicine, GE Medical Systems. 'We are pleased to show our customers how GE and Cytogen products can offer physicians improved diagnostic confidence.'

The new GE/Cytogen relationship will allow the advanced technology of ProstaScint molecular imaging to reach a broader base of customers. The agreement provides that both parties will work together to advance patient and physician awareness of fusion imaging. GE Medical Systems will maintain installation and customer service activities, while Cytogen will provide technical support for ProstaScint fusion imaging.

There are more than 200 GE Hawkeye SPECT/CT systems installed globally. Leading medical centers that offer ProstaScint fusion imaging on this system in the United States are located in such cities as New York (tri-state area), San Francisco, Baltimore and Houston.

Prostate cancer is the second leading cause of cancer-related death among men. According to the American Cancer Society, in this year alone, 220,900 men are expected to be diagnosed with the cancer and approximately 28,900 will die from the disease.

'The public's growing awareness of the importance of accurately staging the extent and spread of prostate cancer has been a key factor in the creation of the GE Medical Systems/Cytogen alliance,'said Michael D. Becker, president and CEO of Cytogen Corporation. 'GE Medical Systems is a respected name in medical imaging technology and equipment, and we are pleased to support molecular imaging through our technical support specialists. Recent advances in molecular imaging technology, made possible by novel systems such as the GE Infinia Hawkeye series, are critical to realizing future potential growth for ProstaScint by enhancing image quality and addressing the historical limitations of SPECT agents.'

About GE Medical Systems

GE Medical Systems is a $9 billion global leader in medical imaging, interventional procedures, healthcare services, and information technology. Its offerings include networking and productivity tools, clinical information systems, patient monitoring systems, surgery and vascular imaging, conventional and digital X-ray, computed tomography, electron beam tomography, magnetic resonance, ultrasound and bone mineral densitometry, positron emission tomography, nuclear medicine, and a comprehensive portfolio of clinical and business services. For more than 100 years, health care providers worldwide have relied on GE Medical Systems for high quality medical technology and productivity solutions. For more information, visit the GE Medical Systems Web site at www.gemedical.com.

About Cytogen Corporation

Cytogen Corporation of Princeton, NJ is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets proprietary and licensed oncology products through its in-house specialty sales force: ProstaScint(R) (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer) and NMP22(R) BladderChek(TM) (a point-of-care, in vitro diagnostic test for bladder cancer). Cytogen has also developed Quadramet(R), a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer, for which the company receives royalties on product sales through Berlex Laboratories, the U.S. affiliate of Schering AG Germany, which markets the product in the United States. Cytogen has exclusive U.S. marketing rights to Combidex(R), an ultrasmall superparamagnetic iron oxide (USPIO) contrast agent for magnetic resonance imaging of lymph nodes that is pending clearance by the U.S. Food and Drug Administration. Cytogen's pipeline comprises product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA (prostate specific membrane antigen) technology, which was exclusively licensed from Memorial Sloan-Kettering Cancer Center. Cytogen also conducts research in cellular signaling through its AxCell Biosciences research division in Newtown, PA. For more information, please visit the Company's website at www.cytogen.com, which is not part of this press release.

This press release contains certain 'forward-looking'statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words 'anticipates,''believes,''estimates,' 'expects,''intends,''may,''plans,''projects,''will,''would'and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward- looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. The Company cannot guarantee that the Company will actually achieve the plans, intentions or expectations disclosed in any such forward-looking statements. The Company's actual results may differ materially from the Company's historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to, the Company's ability to carry out its business and financial plans, to determine and implement the appropriate strategic initiative for its AxCell Biosciences subsidiary, to fund development necessary for existing products and to pursue new product opportunities, the risk of whether products result from development activities, protection of its intellectual property portfolio, ability to integrate in-licensed products such as NMP22(R) BladderChek(TM), ability to establish and successfully complete clinical trials where required for product approval, the risk associated with obtaining the necessary regulatory approvals, shifts in the regulatory environment affecting sales of the Company's products such as third-party payor reimbursement issues, dependence on the Company's partners for development of certain projects, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other factors discussed in the Company's Form 10-K for the year ended December 31, 2002, as amended, and from time-to-time in the Company's other filings with the Securities and Exchange Commission. Any forward-looking statements made by the Company do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments the Company may make. The Company does not assume, and specifically disclaims, any obligation to update any forward-looking statements, and these statements represent the Company's current outlook only as of the date given.

SOURCE GE Medical Systems; Cytogen Corporation

Stacy Shearer of Cytogen Corporation, +1-609-750-8275, This email address is being protected from spambots. You need JavaScript enabled to view it.; or Marshall Poindexter of GE Medical Systems,+1-262-513-4016, This email address is being protected from spambots. You need JavaScript enabled to view it./Web sites: http://www.cytogen.comhttp://www.gemedical.com(CYTO GE)

WEBSITE This email address is being protected from spambots. You need JavaScript enabled to view it.